Similar articles

• Comparing ranibizumab with bevacizumab.

  Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Biswas P, et al. Ophthalmology. 2011 Mar;118(3):600-600.e2. doi: 10.1016/j.ophtha.2010.10.027. Ophthalmology. 2011. PMID: 21376243 Clinical Trial. No abstract available.
• Intravitreal bevacizumab.

  Lucas RS, McKee HD, Lee LR. Lucas RS, et al. Ophthalmology. 2007 Feb;114(2):400; author reply 400-1. doi: 10.1016/j.ophtha.2006.10.002. Ophthalmology. 2007. PMID: 17270701 No abstract available.
• Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

  Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group. Arevalo JF, et al. Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4. Retina. 2008. PMID: 18827735
• Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.

  El-Mollayess GM, Noureddine BN, Bashshur ZF. El-Mollayess GM, et al. Semin Ophthalmol. 2011 May;26(3):69-76. doi: 10.3109/08820538.2010.545100. Semin Ophthalmol. 2011. PMID: 21609219 Review.
• Preferred therapies for neovascular age-related macular degeneration.

  Chiang A, Regillo CD. Chiang A, et al. Curr Opin Ophthalmol. 2011 May;22(3):199-204. doi: 10.1097/ICU.0b013e32834597d9. Curr Opin Ophthalmol. 2011. PMID: 21427571 Review.